2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 760 | - | - | ||
| 1 970 | - | - | ||
| 14 991 | - | - | ||
| 688 | - | - | ||
| 502 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·22 min sitten · MuokattuManagement was incredibly skilled and capitalized on the wild surge last year. Even though this puts the nail in the coffin and the stock will probably fall towards 3 in the short term. It exudes Professionalism from the action.
·2 t sittenA small observation: AstraZeneca posted a position in August as "Executive Director, Cancer Vaccine Discovery". The role would, among other things, build a portfolio in cancer vaccines and work with neoantigens, mRNA delivery, and external collaborations. Of course, this doesn't mean that the guys at AstraZeneca will come knocking on Nykode's door tomorrow. But I think it's an interesting signal of where the field is moving. Personal/neoantigen-based cancer vaccines increasingly appear to be an area Big Pharma wants exposure to. And precisely there, Nykode is already well-positioned with VB10.NEO, NeoSELECT, and its own experience from clinical studies.
·2 t sittenWhy is the share sold so much below the issue price. Strange things!!57 min sittenJust to add. Don't anchor on what other people have paid for the share, it is a fair sign that there is faith in the vision, but learning not to anchor a price is something easier said than done 🙂
·3 t sittenSent the following message to the company: First, I have a tiny bit of understanding that you carried out a directed issue to exploit the market now. But at the same time, some warning signs, with ABG in the morning setting a new price target of kr 7 BEFORE the announcement of the issue, with the text "a cash balance that will very likely last into 2029". This the day after the announcement of a preliminary ruling that we are winning the Tax Case. Then comes the announcement of a directed issue after market close where ABG will be involved in the arrangement. It gets oversubscribed, then the same text comes out: "Provided a positive final outcome in the ongoing tax case, Nykode expects that the proceeds from the issue, together with existing cash balance, will provide the company with financing well into 2029." I.e., exactly the same text as in the price target BEFORE the issue. Here there is a logical flaw! As there is a lot of money involved in both the tax case AND the issue. Both separately provide liquidity for at least 1 extra year along with cost reduction. You had such momentum in the market now with indirect help from Big Pharma and good results, as well as having won the tax case and a price target of 7 (which in this setting then seems suspicious). That you could well have waited up to 1 year before the issue, most likely at a much higher price. I know no one can predict the future, but if you are so positive, you should have waited, it gives an ambivalent signal to us shareholders that you carried out the issue now since you are almost guaranteed repayment of tax + interest. Can you comment on this? There is no mention that you might scale up any research, accelerate stages that will entail extra cost for these 65 mill * 4.4 = NOK 286 mill over the next 3 years? At the same time, I see that several "medium" large shareholders have sold out in the Issue? Among others, Omen holding + various Funds. Was this carried out as a coordinated Block sale, where they offered their shares in the issue to new actors? If so, you are obliged to inform about this in the stock exchange announcements. Otherwise, this also seems suspicious that it happened on the same day, as I assume all of these have been asked to participate. Do you have a comment on that?
A bit unsure 🤷♂️ which way to lean. 📍Andenæs, who accepted a 50% allocation, should at least acquire shares below the issue price. 📍There is something that seems "rushed" with the process from quarterly presentation to emission. Ref. analysis and positive events like Moderna and the tax case. 📍There is also a greater possibility that more will come later in the autumn, which increases the explanatory power EriHof is a master at describing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·22 min sitten · MuokattuManagement was incredibly skilled and capitalized on the wild surge last year. Even though this puts the nail in the coffin and the stock will probably fall towards 3 in the short term. It exudes Professionalism from the action.
- ·2 t sittenA small observation: AstraZeneca posted a position in August as "Executive Director, Cancer Vaccine Discovery". The role would, among other things, build a portfolio in cancer vaccines and work with neoantigens, mRNA delivery, and external collaborations. Of course, this doesn't mean that the guys at AstraZeneca will come knocking on Nykode's door tomorrow. But I think it's an interesting signal of where the field is moving. Personal/neoantigen-based cancer vaccines increasingly appear to be an area Big Pharma wants exposure to. And precisely there, Nykode is already well-positioned with VB10.NEO, NeoSELECT, and its own experience from clinical studies.
- ·2 t sittenWhy is the share sold so much below the issue price. Strange things!!57 min sittenJust to add. Don't anchor on what other people have paid for the share, it is a fair sign that there is faith in the vision, but learning not to anchor a price is something easier said than done 🙂
- ·3 t sittenSent the following message to the company: First, I have a tiny bit of understanding that you carried out a directed issue to exploit the market now. But at the same time, some warning signs, with ABG in the morning setting a new price target of kr 7 BEFORE the announcement of the issue, with the text "a cash balance that will very likely last into 2029". This the day after the announcement of a preliminary ruling that we are winning the Tax Case. Then comes the announcement of a directed issue after market close where ABG will be involved in the arrangement. It gets oversubscribed, then the same text comes out: "Provided a positive final outcome in the ongoing tax case, Nykode expects that the proceeds from the issue, together with existing cash balance, will provide the company with financing well into 2029." I.e., exactly the same text as in the price target BEFORE the issue. Here there is a logical flaw! As there is a lot of money involved in both the tax case AND the issue. Both separately provide liquidity for at least 1 extra year along with cost reduction. You had such momentum in the market now with indirect help from Big Pharma and good results, as well as having won the tax case and a price target of 7 (which in this setting then seems suspicious). That you could well have waited up to 1 year before the issue, most likely at a much higher price. I know no one can predict the future, but if you are so positive, you should have waited, it gives an ambivalent signal to us shareholders that you carried out the issue now since you are almost guaranteed repayment of tax + interest. Can you comment on this? There is no mention that you might scale up any research, accelerate stages that will entail extra cost for these 65 mill * 4.4 = NOK 286 mill over the next 3 years? At the same time, I see that several "medium" large shareholders have sold out in the Issue? Among others, Omen holding + various Funds. Was this carried out as a coordinated Block sale, where they offered their shares in the issue to new actors? If so, you are obliged to inform about this in the stock exchange announcements. Otherwise, this also seems suspicious that it happened on the same day, as I assume all of these have been asked to participate. Do you have a comment on that?A bit unsure 🤷♂️ which way to lean. 📍Andenæs, who accepted a 50% allocation, should at least acquire shares below the issue price. 📍There is something that seems "rushed" with the process from quarterly presentation to emission. Ref. analysis and positive events like Moderna and the tax case. 📍There is also a greater possibility that more will come later in the autumn, which increases the explanatory power EriHof is a master at describing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 760 | - | - | ||
| 1 970 | - | - | ||
| 14 991 | - | - | ||
| 688 | - | - | ||
| 502 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·22 min sitten · MuokattuManagement was incredibly skilled and capitalized on the wild surge last year. Even though this puts the nail in the coffin and the stock will probably fall towards 3 in the short term. It exudes Professionalism from the action.
- ·2 t sittenA small observation: AstraZeneca posted a position in August as "Executive Director, Cancer Vaccine Discovery". The role would, among other things, build a portfolio in cancer vaccines and work with neoantigens, mRNA delivery, and external collaborations. Of course, this doesn't mean that the guys at AstraZeneca will come knocking on Nykode's door tomorrow. But I think it's an interesting signal of where the field is moving. Personal/neoantigen-based cancer vaccines increasingly appear to be an area Big Pharma wants exposure to. And precisely there, Nykode is already well-positioned with VB10.NEO, NeoSELECT, and its own experience from clinical studies.
- ·2 t sittenWhy is the share sold so much below the issue price. Strange things!!57 min sittenJust to add. Don't anchor on what other people have paid for the share, it is a fair sign that there is faith in the vision, but learning not to anchor a price is something easier said than done 🙂
- ·3 t sittenSent the following message to the company: First, I have a tiny bit of understanding that you carried out a directed issue to exploit the market now. But at the same time, some warning signs, with ABG in the morning setting a new price target of kr 7 BEFORE the announcement of the issue, with the text "a cash balance that will very likely last into 2029". This the day after the announcement of a preliminary ruling that we are winning the Tax Case. Then comes the announcement of a directed issue after market close where ABG will be involved in the arrangement. It gets oversubscribed, then the same text comes out: "Provided a positive final outcome in the ongoing tax case, Nykode expects that the proceeds from the issue, together with existing cash balance, will provide the company with financing well into 2029." I.e., exactly the same text as in the price target BEFORE the issue. Here there is a logical flaw! As there is a lot of money involved in both the tax case AND the issue. Both separately provide liquidity for at least 1 extra year along with cost reduction. You had such momentum in the market now with indirect help from Big Pharma and good results, as well as having won the tax case and a price target of 7 (which in this setting then seems suspicious). That you could well have waited up to 1 year before the issue, most likely at a much higher price. I know no one can predict the future, but if you are so positive, you should have waited, it gives an ambivalent signal to us shareholders that you carried out the issue now since you are almost guaranteed repayment of tax + interest. Can you comment on this? There is no mention that you might scale up any research, accelerate stages that will entail extra cost for these 65 mill * 4.4 = NOK 286 mill over the next 3 years? At the same time, I see that several "medium" large shareholders have sold out in the Issue? Among others, Omen holding + various Funds. Was this carried out as a coordinated Block sale, where they offered their shares in the issue to new actors? If so, you are obliged to inform about this in the stock exchange announcements. Otherwise, this also seems suspicious that it happened on the same day, as I assume all of these have been asked to participate. Do you have a comment on that?A bit unsure 🤷♂️ which way to lean. 📍Andenæs, who accepted a 50% allocation, should at least acquire shares below the issue price. 📍There is something that seems "rushed" with the process from quarterly presentation to emission. Ref. analysis and positive events like Moderna and the tax case. 📍There is also a greater possibility that more will come later in the autumn, which increases the explanatory power EriHof is a master at describing.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 760 | - | - | ||
| 1 970 | - | - | ||
| 14 991 | - | - | ||
| 688 | - | - | ||
| 502 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt